Login
Companies $GANX
$0.94 -$0.00 (0.01%) After hours
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc.

gaintherapeutics.com

What Do They Do?

Develops small-molecule drug candidates for people with Parkinson’s disease and other neurological, metabolic and storage disorders, using a computational platform to identify compounds that alter disease-related proteins.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +40% (Loss)
vs −$5.3M in Q3 FY2025
  • Sep 22, 2026 CEO took interim finance duties after finance officer resigned Gene Mack assumed the principal financial officer and accounting officer duties while the company searched for a permanent replacement.

Broader Parkinson’s disease focus The lead candidate was described as targeting a genetic form of Parkinson’s disease; the latest report describes it for Parkinson’s disease both with and without the associated mutation.

Narrower pipeline emphasis The older report described programs in Parkinson’s and Gaucher disease, Krabbe disease, liver and lung disease, and oncology; the latest centers on advancing the Parkinson’s lead program while continuing other research programs.

Who Do They Compete With?

Competes with Vanqua Bio, BIAL, Caraway Therapeutics, Prevail Therapeutics, and Voyager Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support